{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T18:00:19Z","timestamp":1648576819211},"reference-count":10,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.medcli.2011.10.021","type":"journal-article","created":{"date-parts":[[2011,12,23]],"date-time":"2011-12-23T07:19:41Z","timestamp":1324624781000},"page":"685-686","source":"Crossref","is-referenced-by-count":0,"title":["Tratamiento combinado a largo plazo con cinacalcet y bisfosfonatos en el hiperparatiroidismo primario persistente tras cirug\u00eda"],"prefix":"10.1016","volume":"138","author":[{"given":"Pedro","family":"Iglesias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Carlos","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2011.10.021_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jc.2008-1763","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop","volume":"94","author":"Bilezikian","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2011.10.021_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/pgmj.2008.070177","article-title":"Current treatments in the management of patients with primary hyperparathyroidism","volume":"999","author":"Iglesias","year":"2009","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.medcli.2011.10.021_bib0015","doi-asserted-by":"crossref","first-page":"415719","DOI":"10.1155\/2011\/415719","article-title":"Cinacalcet treatment of primary hyperparathyroidism","volume":"2011","author":"Rothe","year":"2011","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.medcli.2011.10.021_bib0020","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism","volume":"12","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2011.10.021_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MAJ.0b013e3181379f3e","article-title":"Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy","volume":"2","author":"Iglesias","year":"2008","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.medcli.2011.10.021_bib0030","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"12","author":"Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2011.10.021_bib0035","article-title":"Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling","author":"Cetani","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.medcli.2011.10.021_bib0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"3","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"key":"10.1016\/j.medcli.2011.10.021_bib0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism","volume":"1","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.medcli.2011.10.021_bib0050","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4158\/EP08178.ORR","article-title":"Alendronate therapy in men with primary hyperparathyroidism","volume":"7","author":"Khan","year":"2009","journal-title":"Endocr Pract"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775311010773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775311010773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T09:55:59Z","timestamp":1543312559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775311010773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":10,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0025775311010773"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2011.10.021","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}